Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsASX:BLS 46 PS Ratio is 4.92 as of Jul. 14, 2026, which is 4% above its 10-year median of 4.73. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 930 Biotechnology companies, BLS Pharmaceuticals ranks better than 66.67% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BLS Pharmaceuticals's share price is A$0.97.
BLS Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.20. Hence, BLS Pharmaceuticals's PS Ratio for today is 4.92.
Warning Sign:
BLS Pharmaceuticals Ltd stock PS Ratio (=7.95) is close to 1-year high of 8.61.
The historical rank and industry rank for BLS Pharmaceuticals's PS Ratio or its related term are showing as below:
ASX:BLS'
s PS Ratio Range Over the Past 10 Years
Min: 1.04 Med: 4.73 Max: 15.79
Current: 4.92
During the past 13 years, BLS Pharmaceuticals's highest PS Ratio was 15.79. The lowest was 1.04. And the median was 4.73.
ASX:BLS's PS Ratio is ranked better than 66.67% of 930
companies
in the Biotechnology industry
Industry Median: 9.405
vs ASX:BLS: 4.92
During the past 12 months, the average Revenue per Share Growth Rate of BLS Pharmaceuticals was 134.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 47.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 23.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 1.00% per year.
During the past 13 years, BLS Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 105.40% per year. The lowest was -79.10% per year. And the median was -13.20% per year.
Back to Basics: PS Ratio
BLS Pharmaceuticals (ASX:BLS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
BLS Pharmaceuticals PS Ratio Related Terms
BLS Pharmaceuticals PS Ratio Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
BLS Pharmaceuticals's Share Price of today is A$0.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.20.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
BLS Pharmaceuticals (ASX:BLS) has a PS Ratio of 4.92 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BLS Pharmaceuticals and its competitors. This is near median its historical median of 4.73. Over the past decade, BLS Pharmaceuticals' PS Ratio has ranged from 1.04 to 15.79. According to the industry distribution chart, BLS Pharmaceuticals ranks #310 out of 930 companies in the Biotechnology industry, placing it in the top 33.3%.
Is BLS Pharmaceuticals' PS Ratio too high?
BLS Pharmaceuticals' current PS Ratio of 4.92 is near median its 10-year median of 4.73. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 15.79. The Biotechnology industry median PS Ratio is 9.41. BLS Pharmaceuticals' value of 4.92 is 47.7% below this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #310 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' PS Ratio compare to KHC and GIS?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #310 out of 930 companies for PS Ratio. This puts BLS Pharmaceuticals in the upper half of its industry. The industry median PS Ratio is 9.41. BLS Pharmaceuticals' value of 4.92 is 47.7% below this benchmark. Historically, BLS Pharmaceuticals' own PS Ratio has ranged from 1.04 to 15.79 over the past decade. While the company's 10-year median is 4.73 vs. the industry median of 9.41, BLS Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.41, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current PS Ratio of 4.92 is 47.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current PS Ratio is 4.92, which is near median its own 10-year median of 4.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.97 — trading 40.6% above its estimated fair value. The current PS Ratio is 4.92, which is near median its 10-year median of 4.73 and 47.7% below the Biotechnology industry median of 9.41. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current PS Ratio is 4.92 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:BLS:
PS Ratio: 4.92 (near median its 10-year median of 4.73)
GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
Industry Position: 47.7% below the Biotechnology median (#310 of 930)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
